Hepatitis B Co-Infection is Associated with Poorer Survival of HIV-Infected Patients on Highly Active Antiretroviral Therapy in West Africa

DSpace/Manakin Repository

Hepatitis B Co-Infection is Associated with Poorer Survival of HIV-Infected Patients on Highly Active Antiretroviral Therapy in West Africa

Show simple item record

dc.contributor.author G Ladep, Nimzing
dc.contributor.author Agbahi, Oche O
dc.contributor.author Agaba, Patricia A
dc.contributor.author Muazu, Auwal
dc.contributor.author Ugoagwu, Placid
dc.contributor.author Imade, Godwin
dc.contributor.author Cooke, Graham S.
dc.contributor.author Vivas, Livia
dc.contributor.author McCormack, Sheena
dc.contributor.author Taylor-Robinson, Simon D
dc.contributor.author Idoko, John
dc.contributor.author Kanki, Phyllis Jean
dc.date.accessioned 2016-05-03T18:52:21Z
dc.date.issued 2013
dc.identifier.citation G Ladep, Nimzing, et all. 2013. “Hepatitis B Co-Infection Is Associated with Poorer Survival of HIV-Infected Patients on Highly Active Antiretroviral Therapy in West Africa.” Journal of AIDS & Clinical Research 01 (S3). doi:10.4172/2155-6113.s3-006. en_US
dc.identifier.issn 2155-6113 en_US
dc.identifier.uri http://nrs.harvard.edu/urn-3:HUL.InstRepos:26878043
dc.description.abstract Background: Hepatitis B has been reported to be high in HIV-infected African populations. However, the impact of this co-infection on the survival of HIV-infected Africans on long-term highly active antiretroviral therapy (HAART) remains poorly characterised. We investigated the impact of HBV/HIV co-infection on survival of HIV infected patients undergoing antiretroviral therapy in a West African population. Methods: This was a clinic-based cohort study of HIV-infected adults enrolled in Nigeria, West Africa. Study subjects (9,758) were screened for hepatitis B and hepatitis C at HAART initiation. Kaplan-Meier survival and Cox proportional hazards models were used to estimate probability of survival and to identify predictors of mortality respectively, based on hepatitis B surface antigen status. All patients had signed an informed written consent before enrolment into the study; and we additionally obtained permission for secondary use of data from the Harvard institutional review board. Results: Patients were followed up for a median of 41 months (interquartile range: 30–62 months) during which, 181 (1.9%) patients died. Most of the deaths; 143 (79.0%) occurred prior to availability of Tenofovir. Among those that were on antiretroviral therapy, hepatitis B co-infected patients experienced a significantly lower survival than HIV mono-infected patients at 74 months of follow up (94% vs. 97%; p=0.0097). Generally, hepatitis B co-infection: HBsAg-positive/HIV-positive (Hazards Rate [HR]; 1.5: 95% CI 1.09–2.11), co-morbid tuberculosis (HR; 2.2: 95% CI 1.57–2.96) and male gender (HR; 1.5: 95% CI 1.08–2.00) were significantly predictive of mortality. Categorising the patients based on use of Tenofovir, HBV infection failed to become a predictor of mortality among those on Tenofovir-containing HAART. Conclusions: HBsAg-positive status was associated with reduced survival and was an independent predictor of mortality in this African HIV cohort on HAART. However, Tenofovir annulled the impact of HBV on mortality of HIV patients in the present study cohort. en_US
dc.language.iso en_US en_US
dc.publisher OMICS Publishing Group en_US
dc.relation.isversionof doi:10.4172/2155-6113.S3-006 en_US
dc.relation.hasversion http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4199237/ en_US
dash.license OAP
dc.subject mortality en_US
dc.subject hepatitis B surface antigen en_US
dc.subject HIV en_US
dc.subject CD4 en_US
dc.subject HAART en_US
dc.subject survival en_US
dc.subject Africa en_US
dc.title Hepatitis B Co-Infection is Associated with Poorer Survival of HIV-Infected Patients on Highly Active Antiretroviral Therapy in West Africa en_US
dc.type Journal Article en_US
dc.description.version Accepted Manuscript en_US
dc.relation.journal J AIDS Clin Res en_US
dash.depositing.author Kanki, Phyllis Jean
dc.date.available 2016-05-03T18:52:21Z
dash.funder.name US Health Resources and Services Administration en_US
dash.funder.name NIH en_US
dash.funder.award U51HA02522-01-01 en_US
dash.funder.award R24TW008878 en_US

Files in this item

Files Size Format View
nihms588428.pdf 610.5Kb PDF View/Open

This item appears in the following Collection(s)

Show simple item record

 
 

Search DASH


Advanced Search
 
 

Submitters